NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- According to a new research report titled “Hyperlipidemia Therapeutics Pipeline Analysis 2018” published by P&S Market Research, Hyperlipidemia therapeutics currently exhibits a strong pipeline with 53 drug candidates.
Request for Sample Copy of this Research Report: https://www.psmarketresearch.com/market-analysis/hyperlipidemia-therapeutics-pipeline-analysis/report-sample
Hyperlipidemia refers to elevated amount of lipids and cholesterol in the bloodstream. The two major types of lipid abnormalities are characterized by either high blood levels of triglycerides (known as hypertriglyceridemia) or high blood cholesterol levels (known as hypercholesterolemia). Hyperlipidemia is often associated with increased risk of coronary heart disease and strokes. The study analyzed that hyperlipidemia therapeutics pipeline comprises 53 drug candidates in different stages of development.
According to the research findings, a majority of the drug candidates for the treatment of hyperlipidemia are being developed to be administered by the oral route, which is convenient to take, and has been considered as non-invasive, often safer route that requires no special training to the patients.
Hyperlipidemia increases cardiovascular risks and lowering elevated Low-Density Lipoprotein-Cholesterol (LDL-C) remains a significant unmet need. Statins are the standard of care available for patients with hypercholesterolemia and are highly effective at lowering LDL-C, with well-documented benefits. However, it is unable to achieve a permanent treatment care for all subset of patients.
Browse Full Report with detailed TOC on “Hyperlipidemia Therapeutics Pipeline” at: https://www.psmarketresearch.com/market-analysis/hyperlipidemia-therapeutics-pipeline-analysis
It has been observed that most of the companies are developing drug candidates that involves novel target. Also, the drug candidates have showed positive efficacy in the clinical as well as Pre-Clinical stage of development. For instance, Inclisiran is under the Phase III stage of development by The Medicines Company for the treatment of hyperlipidemia. The drug candidate is an RNAi that targets proprotein convertase subtilisin/kexin type 9 (PCSK9) protein and RNA interference. It was found that Inclisiran cause sustained reductions in low-density lipoprotein (LDL) cholesterol levels over the course of 84 days in healthy volunteers.
Similarly, LY3015014 is under the Phase II stage of development by Eli Lilly and Company that target PCSK9 protein inhibitor. DCR-PCSK9 is a Pre-Clinical drug candidate of Dicerna Pharmaceuticals Inc.
Some of the key players involved in the development of hyperlipidemia therapeutics include Novartis AG, Eli Lilly and Company and Merck & Co. Inc.
More Reports Published by P&S Market Research
Nuclear factor-kappa B Inhibitors Therapeutics Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/nf-kb-inhibitors-therapeutics-pipeline-analysis
Proteasome Inhibitors Therapeutics Pipeline - https://www.psmarketresearch.com/market-analysis/proteasome-inhibitors-therapeutics
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com